Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer E Morgan

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Plos One|March 3, 2011
Uncoordinated transcription and compromised muscle function in the lmna-null mouse model of Emery- Emery-Dreyfuss muscular dystrophyViola F Gnocchi, Juergen Scharner, Zhe Huang, et al.
Neuromuscular Disorders : NMD|January 19, 2010
Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trialsLinda J Popplewell, Carl Adkin, Virginia Arechavala-Gomeza, et al.
Scientific Reports|August 30, 2017
Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Scientific Reports|March 3, 2017
Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Nature Communications|October 4, 2018
Publisher Correction: Necroptosis mediates myofibre death in dystrophin-deficient miceJennifer E Morgan, Alexandre Prola, Virginie Mariot, et al.
Nature Communications|September 9, 2018
Necroptosis mediates myofibre death in dystrophin-deficient miceJennifer E Morgan, Alexandre Prola, Virginie Mariot, et al.
Scientific Reports|March 18, 2017
Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Human Molecular Genetics|July 29, 2016
Selective release of muscle-specific, extracellular microRNAs during myogenic differentiationAnna M L Coenen-Stass, Corinne A Betts, Yi F Lee, et al.
Neuromuscular Disorders : NMD|April 17, 2010
Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trialsVirginia Arechavala-Gomeza, Maria Kinali, Lucy Feng, et al.
Plos One|November 28, 2013
Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular DystrophyIrina T Zaharieva, Mattia Calissano, Mariacristina Scoto, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Plos One|March 3, 2011
Uncoordinated transcription and compromised muscle function in the lmna-null mouse model of Emery- Emery-Dreyfuss muscular dystrophyViola F Gnocchi, Juergen Scharner, Zhe Huang, et al.
Neuromuscular Disorders : NMD|January 19, 2010
Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trialsLinda J Popplewell, Carl Adkin, Virginia Arechavala-Gomeza, et al.
Scientific Reports|August 30, 2017
Erratum: Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Scientific Reports|March 3, 2017
Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Nature Communications|October 4, 2018
Publisher Correction: Necroptosis mediates myofibre death in dystrophin-deficient miceJennifer E Morgan, Alexandre Prola, Virginie Mariot, et al.
Nature Communications|September 9, 2018
Necroptosis mediates myofibre death in dystrophin-deficient miceJennifer E Morgan, Alexandre Prola, Virginie Mariot, et al.
Scientific Reports|March 18, 2017
Lentiviral vectors can be used for full-length dystrophin gene therapyJohn R Counsell, Zeinab Asgarian, Jinhong Meng, et al.
Human Molecular Genetics|July 29, 2016
Selective release of muscle-specific, extracellular microRNAs during myogenic differentiationAnna M L Coenen-Stass, Corinne A Betts, Yi F Lee, et al.
Neuromuscular Disorders : NMD|April 17, 2010
Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trialsVirginia Arechavala-Gomeza, Maria Kinali, Lucy Feng, et al.
Plos One|November 28, 2013
Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular DystrophyIrina T Zaharieva, Mattia Calissano, Mariacristina Scoto, et al.
Pageof 8